Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 258 across all filing types
Latest filing 2022-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming 21st Annual General Meeting (AGM) of Ensol Biosciences. It includes the purpose of the meeting, voting procedures (electronic/proxy), and agenda items such as financial statement approval and director appointments. This document is a formal solicitation of proxies for a shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) for Ensol Biosciences. It outlines the date, location, agenda items (financial statement approval, director/auditor appointments, and compensation limits), and details regarding electronic voting. This document serves as the official solicitation and notification to shareholders regarding the upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-03-11 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 100% confidence The document is an official notice regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of filing relates to changes in the company's capital structure and financial instruments. According to the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate classification for updates on financing activities and capital structure changes, including convertible bond adjustments.
2022-02-16 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details specific changes to the company's board of directors, including the names of the outgoing and incoming outside directors, their backgrounds, and the reasons for their departure. This falls directly under the category of Board/Management Information (MANG).
2022-01-17 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the regulator that does not fit into more specific categories like DIRS (which is for director/insider trading) or SHA (which is for general share issuance).
2022-01-17 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for Ensol Biosciences. It details the voting outcomes for specific agenda items, such as the appointment of outside directors and stock option grants. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2022-01-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.